A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs)
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs BMS 813160 (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2019 Planned initiation date changed from 1 Aug 2019 to 1 Nov 2019.
- 03 Jul 2019 Planned initiation date changed from 1 Jun 2019 to 1 Aug 2019.
- 21 May 2019 Planned initiation date changed from 1 May 2019 to 1 Jun 2019.